Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent

Ernexa Therapeutics Inc.

Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
Approved amendment to increase authorized common stock from 100M to 150M shares.
Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.
Approved stockholder action by written consent, removing meeting-only requirement.
Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement.

item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ernexa Therapeutics Inc.: Allowed stockholder action by written consent in addition to meetings (effective 2025-06-02).

Change: charter amendment
Effective: 2025-06-02

Exact text from the filing

Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ernexa Therapeutics Inc.: Increased authorized common stock from 100,000,000 to 150,000,000 (effective 2025-06-02).

Change: charter amendment
Effective: 2025-06-02

Exact text from the filing

Effective June 2, 2025, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Amended COI”) with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.

View on SEC.gov

Browse all governance changes →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-013249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.